Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Expert Opinion / Commentary · December 20, 2022

2022 Top Story in Oncology: The Pursuit of Minimal Residual Disease Negativity as the Main Goal of Multiple Myeloma Therapy

Written by
Rafael Fonseca MD


Additional Info

  1. Landgren O, Devlin S, Boulad M, et al. Role of MRD Status in Relation to Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients: A Meta-Analysis. Bone Marrow Transplant. 2016;51(12):1565-1568.
  2. Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncol. 2017;3(1):28-35.
  3. Munshi NC, Avet-Loiseau H, Anderson KC, et al. A Large Meta-Analysis Establishes the Role of MRD Negativity in Long-Term Survival Outcomes in Patients With Multiple Myeloma. Blood Adv. 2020;4(23):5988-5999.
  4. de Tute RM, Pawlyn C, Cairns DA, et al. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. J Clin Oncol. 2022;40(25):2889-2900.
  5. Paiva B, Puig N, Cedena MT, et al. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. J Clin Oncol. 2020;38(8):784-792.
  6. Paiva B, Manrique I, Dimopoulos MA, et al. MRD Dynamics During Maintenance for Improved Prognostication of 1280 Myeloma Patients in TOURMALINE-MM3 and -MM4 trials. Blood. 2022 Sep 21. Doi: 10.1182/blood.2022016782. Online ahead of print.
  7. Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456-2464.
  8. Moreau P, Attal M, Hulin C, et al. Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab Before and After Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study. Lancet. 2019;394(10192):29-38.

Disclosure statements are available on the authors' profiles:

Further Reading